Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines
Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Although glycoconjugate vaccines are generally very efficacious, there is still a need to improve their efficacy, especially in eliciting a strong primary antibody response. We have recently described a new type of vaccine adjuvant based on a TLR7 agonist adsorbed to alum (Alum-TLR7), which is highly efficacious at enhancing immunogenicity of prote...
Alternative Titles
Full title
Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4954951
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4954951
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/srep29063
